RxDoctor Payments Data

Anne Cummings, MD

Internal Medicine · Greenbrae, CANPI 1619917028

Payments from drug & device makers

$2,997in general payments, 2019–2025

Across 125 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$487
  • Amgen$452
  • Novo Nordisk$393
  • Astellas Pharma US Inc$279
  • Lilly USA, LLC$265
  • AbbVie$229
  • plus $892 from 14 others

What the payments were for

  • Food & beverage$2,997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,997 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$329,293
Medicare patients
290
Services billed
5,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide15$50,212
EliquisApixaban54$47,794
JardianceEmpagliflozin13$22,771
JanuviaSitagliptin Phosphate14$22,047
MounjaroTirzepatide23$21,710
BelsomraSuvorexant23$20,905
Repatha SureclickEvolocumab17$13,402
EdarbiAzilsartan Medoxomil16$5,812
Atorvastatin Calcium335$4,767
SynthroidLevothyroxine Sodium48$4,181
Estradiol26$2,926
Levothyroxine Sodium175$2,647
Rosuvastatin Calcium84$2,094
Amlodipine Besylate147$1,700
ValacyclovirValacyclovir Hcl28$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$487$50,21215 claims
PfizerEliquis$18$47,79454 claims
MerckJanuvia, Belsomra$175$42,95237 claims
Lilly USA, LLCMounjaro$265$21,71023 claims
Arbor Pharmaceuticals, Inc.Edarbi$211$5,81216 claims
AbbVieSynthroid$229$4,18148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Greenbrae

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →